A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma
Status:
Terminated
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
This study is a Ph I trial to test the safety of the study drug, hLL1-DOX at different dose
levels in patients with recurrent multiple myeloma. HLL1 is also known as milatuzumab and is
attached to doxorubicin in this clinical trial.